ProCE Banner Activity

Principais estudos sobre HIV que influenciam a minha prática após a CROI 2023

Slideset

Baixe os slides para revisar os resumos dos principais estudos sobre HIV da CROI 2023, incluindo resultados de estudos sobre estratégias de prevenção, terapias de ação prolongada, eventos adversos da TARV, terapias de segunda linha e coinfecção.

Released: March 23, 2023

Share

Faculty

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Joseph J. Eron, Jr.

Joseph J. Eron, Jr., MD

Professor of Medicine, School of Medicine
Herman and Louise Smith Distinguished Professor
Chief, Division of Infectious Diseases
Director, Clinical Core, UNC Center for AIDS Research
Adjunct Professor of Epidemiology
Gillings School of Global Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Monica Gandhi

Monica Gandhi, MD, MPH

Professor of Medicine
Associate Chief, Division of HIV, Infectious Diseases and Global Medicine
Director, Center for AIDS Research
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco 
San Francisco, California

Princy N Kumar

Princy N Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Tropical Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
London, United Kingdom

Babafemi Taiwo

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
Chicago, Illinois

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD: consultor/conselheiro/palestrante: Gilead, GSK, Merck, Theratechnologies, ViiV; pesquisador: Gilead Sciences, GSK, ViiV.

Joseph J. Eron, Jr., MD

Professor of Medicine, School of Medicine
Herman and Louise Smith Distinguished Professor
Chief, Division of Infectious Diseases
Director, Clinical Core, UNC Center for AIDS Research
Adjunct Professor of Epidemiology
Gillings School of Global Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Joseph J. Eron Jr., MD: consultor/conselheiro/palestrante: Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV; pesquisador: Gilead Sciences, ViiV.

Monica Gandhi, MD, MPH

Professor of Medicine
Associate Chief, Division of HIV, Infectious Diseases and Global Medicine
Director, Center for AIDS Research
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco 
San Francisco, California

Monica Gandhi, MD, MPH, não tem relações financeiras relevantes a divulgar.

Princy N Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Tropical Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP: consultora/conselheira/palestrante: Johnson & Johnson, Thera, ViiV; pesquisadora: Merck; ações e opções de ações individuais negociadas publicamente: Gilead, Pfizer.

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead, GSK, MSD, ViiV; researcher: AstraZeneca, Gilead, GSK, MSD, ViiV.

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
Chicago, Illinois

Babafemi Taiwo, MBBS: consultor: Gilead, GlaxoSmithKline, Johnson & Johnson, ViiV.